Advancing Australia’s stereotactic excellence
Icon Group CEO, Mark Middleton OAM, said the new partnership reflects Icon’s long-standing commitment to pushing the boundaries of precision oncology.
“This centre represents the next chapter in Australia’s stereotactic capability,” said Mark. “By bringing Gamma Knife, CyberKnife, and advanced linac technology together under one roof, we’re creating a nationally significant hub for precision medicine, paving the future of cancer care.
“Icon has invested deeply in stereotactic expertise for more than a decade, from clinical leadership to innovation and research.
“This service builds on that foundation and positions Australia at the forefront of world-class, personalised radiotherapy.
“This is more than a technology milestone. It demonstrates how integrated care and strong partnerships can bring the most advanced treatments closer to home for patients in New South Wales, and across the nation.”
Around 50% of all cancer patients require radiation oncology as part of their treatment.
Phased rollout of next-generational capability
The new Icon Cancer Centre is on track to commence in May 2026, with the full suite of stereotactic technologies becoming available to patients over the course of the year.
This staged approach ensures a quality, safe, and coordinated transition of services, while supporting clinical teams across Icon and MUH to integrate workflows, processes, research opportunities and multidisciplinary care models.
